{"id":"580c7beb-b523-5fde-939b-6b706a355b75","stable_key":"e13b03e1-a614-543a-ac1b-97df18cfe30d:iron-fdi-fcm-comparison","predicate":"had_lower_risk_than_fcm_for","statement":"Hypophosphatemia occurred in 7.9% versus 75.0% in trial A and 8.1% versus 73.7% in trial B with derisomaltose versus carboxymaltose.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"5eb1c977-c7b8-50c2-bd92-e0a77d3bca74","mechanism_event_label":"A second pair of trials also found that iron formulations differed in their phosphate effects.","subject":{"id":"b2b2232d-a6d1-51b4-bd27-6c19d12348af","slug":"ferric-derisomaltose","display_name":"Ferric derisomaltose / iron isomaltoside","entity_type_key":"chemical_species"},"object":{"id":"a9c2c212-3b17-56ef-a50d-ff2a9377e2a1","slug":"iron-infusion-hypophosphatemia","display_name":"Hypophosphatemia after intravenous iron","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"5eb1c977-c7b8-50c2-bd92-e0a77d3bca74","stable_key":"e13b03e1-a614-543a-ac1b-97df18cfe30d:iron-fdi-fcm-comparison-event","event_type":"observed_intervention","label":"A second pair of trials also found that iron formulations differed in their phosphate effects.","description":"Hypophosphatemia occurred in 7.9% versus 75.0% in trial A and 8.1% versus 73.7% in trial B with derisomaltose versus carboxymaltose.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"3f2beafe-a8b7-5242-ab5a-7e46ee7b9913","slug":"ferric-carboxymaltose","display_name":"Ferric carboxymaltose","entity_type_key":"chemical_species"},"role":"comparator","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b28dfc54-a5ef-5f9e-ac1f-890b68e58dc3","slug":"inorganic-phosphate","display_name":"Inorganic phosphate","entity_type_key":"chemical_species"},"role":"affected_mineral","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"b2b2232d-a6d1-51b4-bd27-6c19d12348af","slug":"ferric-derisomaltose","display_name":"Ferric derisomaltose / iron isomaltoside","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"a9c2c212-3b17-56ef-a50d-ff2a9377e2a1","slug":"iron-infusion-hypophosphatemia","display_name":"Hypophosphatemia after intravenous iron","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"nutrient_deficiency","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/iron-research/32016310.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"883aac76c40012cb98ac88924e33b33f4985d356302929b8b26931c1869e2f0a\", \"start_char\": 0, \"end_char\": 2731, \"text_sha256\": \"883aac76c40012cb98ac88924e33b33f4985d356302929b8b26931c1869e2f0a\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Two open-label randomized trials","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Ferric derisomaltose 1000 mg once versus ferric carboxymaltose 750 mg twice; 35 days","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Formulation and total regimen differed; no fracture endpoint or identical risk in all populations is inferred.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Iron research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"iron","display_name":"Iron","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"245 adults, predominantly women, without reduced kidney function","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A second pair of trials also found that iron formulations differed in their phosphate effects.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[iron-p32016310] Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. (2020). https://pubmed.ncbi.nlm.nih.gov/32016310/ DOI: 10.1001/jama.2019.22450","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Serum phosphate","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"nutrient_deficiency","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"c6cacd1b-754f-5ca6-ba51-47960d6f43be","evidence_kind":"source_excerpt","locator":"Lines 992-1003","start_line":992,"end_line":1003,"excerpt":"### iron-fdi-fcm-comparison\nHypophosphatemia occurred in 7.9% versus 75.0% in trial A and 8.1% versus 73.7% in trial B with derisomaltose versus carboxymaltose.\nCondition category: nutrient_deficiency\nnutrient_topic: Iron research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A second pair of trials also found that iron formulations differed in their phosphate effects.\norganism: 245 adults, predominantly women, without reduced kidney function\ntissue_or_cell_type: Serum phosphate\nexperimental_model: Two open-label randomized trials\nlimitations: Formulation and total regimen differed; no fracture endpoint or identical risk in all populations is inferred.\nexposure: Ferric derisomaltose 1000 mg once versus ferric carboxymaltose 750 mg twice; 35 days\nevidence_span: {\"source_cache\": \"artifacts/iron-research/32016310.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"883aac76c40012cb98ac88924e33b33f4985d356302929b8b26931c1869e2f0a\", \"start_char\": 0, \"end_char\": 2731, \"text_sha256\": \"883aac76c40012cb98ac88924e33b33f4985d356302929b8b26931c1869e2f0a\"}\n[iron-p32016310] Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. (2020). https://pubmed.ncbi.nlm.nih.gov/32016310/ DOI: 10.1001/jama.2019.22450","model_system":"Two open-label randomized trials","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [iron-p32016310] Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. (2020). https://pubmed.ncbi.nlm.nih.gov/32016310/ DOI: 10.1001/jama.2019.22450","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"1560864c-91d1-58dc-90c4-49bf61aba3de","stable_key":"import-e13b03e1-a614-543a-ac1b-97df18cfe30d","title":"Iron: absorption, trafficking, iron-dependent enzymes and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f9dab767a21c9bbfef3227707fe3c82953536bb1335599dd4ef93b5ea2dbf03f","revision_id":"77700d7f-2902-54b9-adae-8cbc77b24682","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}